William McVicar

William K. McVicar, Ph.D.
Executive Vice President, Chief Scientific Officer

Dr. McVicar joined Inotek Pharmaceuticals as Executive Vice President of Pharmaceutical Development in September of 2007 and was promoted to Chief Scientific Officer in January 2009. His responsibilities include Project Management for all drug development programs, Chemistry and Pharmaceutical Development, Toxicology, Drug Metabolism, non-clinical Pharmacokinetics, Clinical and Regulatory Operations, and Quality.

Dr. McVicar’s career in the pharmaceutical industry spans 20 years. He joined Sandoz Pharmaceuticals in 1988 and in 1990 he started his career in Project Management becoming an International Project Manager in 1993. As such, he managed a series of projects including the lead development projects in collaborations between Novartis (formed in 1995 by the merger of Sandoz and Ciba Giegy) and leading biotechnology companies including Systemics, Inc., and Genetic Therapy, Inc.

In 1996 he moved to RPR Gencell, an independently managed division of Rhone Poulenc Rorer dedicated to the commercialization gene therapy where he ran the Project Planning and Management group and served on the management board. Following the 1998 merger of RPR and HMR to form Aventis, he joined Sepracor, Inc. in Marlborough, MA. As Vice President of Development Operations, he oversaw the development, FDA review and approval of multiple NDAs and SNDAs.

He earned his B.S. in chemistry from SUNY and his Ph.D. in Chemistry from the University of Vermont.